Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | Tl |
| Molecular Weight | 204.3833 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Tl]
InChI
InChIKey=YWUHBIFVNJARPY-UHFFFAOYSA-N
InChI=1S/Tl.H
| Molecular Formula | Tl |
| Molecular Weight | 204.3833 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Thallium is a soft, silvery-white metal that tarnishes easily. Most thallium is used by the electronics industry in photoelectric cells. Thallium oxide is used to produce special glass with a high index of refraction, and also low melting glass that becomes fluid at about 125K. An alloy of mercury containing 8% thallium has a melting point 20°C lower than mercury alone. This can be used in low temperature thermometers and switches. Thallium is more toxic to humans than mercury, cadmium, lead, copper or zinc and has been responsible for many accidental, occupational, deliberate, and therapeutic poisonings since its discovery in 1861. Its chemical behavior resembles the heavy metals (lead, gold and silver) on the one hand and the alkali metals (K, Rb, Cs) on the other. It occurs almost exclusively in natural waters as monovalent thallous cation. The solubility of thallous compounds is relatively high so that monovalent thallium is readily transported through aqueous routes into the environment. Thallium can be transferred from soils to crops readily and accrues in food crops. The fascinating chemistry and high toxicity potential make thallium and its compounds of particular scientific interest and environmental concern. Radioactive isotope thallium-201 is a radiopharmaceutical used in myocardial perfusion imaging (MPI) using either planar or single photon emission computed tomography (SPECT) techniques for the diagnosis and localization of myocardial infarction. Thallium-201 may also have prognostic value regarding survival, when used in the clinically stable patient following the onset of symptoms of an acute myocardial infarction, to assess the site and size of the perfusion defect. Additionally, Thallium-201 may be used in conjunction with exercise stress testing as an adjunct in the diagnosis of ischemic heart disease (atherosclerotic coronary artery disease) and is also indicated for the localization of sites of parathyroid hyperactivity in patients with elevated serum calcium and parathyroid hormone levels.
Originator
Curator's Comment: The discovery of thallium was controversial. William Crookes of the Royal College of Science in London was the first to observe a green line in the spectrum of some impure sulfuric acid, and realised that it meant a new element. He announced his discovery in March 1861 in Chemical News. However, he did very little research into it.
Meanwhile, in 1862, Claude-August Lamy of Lille, France, began to research thallium more thoroughly and even cast a small ingot of the metal itself. The French Academy now credited him its discovery. He sent the ingot to the London International Exhibition of 1862, where it was acclaimed as a new metal and he was awarded a medal. Crookes was furious and so the exhibition committee awarded him a medal as well.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Identification of (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide, ML277, as a novel, potent and selective K(v)7.1 (KCNQ1) potassium channel activator. | 2012-09-15 |
|
| Mitochondrial ROMK channel is a molecular component of mitoK(ATP). | 2012-08-03 |
|
| Identification of novel KCNQ4 openers by a high-throughput fluorescence-based thallium flux assay. | 2011-11-01 |
|
| KCNQ2/3 openers show differential selectivity and site of action across multiple KCNQ channels. | 2011-08-30 |
|
| Identification of quaternary ammonium compounds as potent inhibitors of hERG potassium channels. | 2011-05-01 |
|
| Discovery, characterization, and structure-activity relationships of an inhibitor of inward rectifier potassium (Kir) channels with preference for Kir2.3, Kir3.x, and Kir7.1. | 2011 |
|
| Profiling diverse compounds by flux- and electrophysiology-based primary screens for inhibition of human Ether-à-go-go related gene potassium channels. | 2010-12 |
|
| Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting. | 2010-12 |
|
| A comparison of hepatocyte cytotoxic mechanisms for thallium (I) and thallium (III). | 2010-10 |
|
| An examination of the association of selected toxic metals with total and central obesity indices: NHANES 99-02. | 2010-09 |
|
| Cell-based potassium ion channel screening using the FluxOR assay. | 2010-04 |
|
| A thallium transport FLIPR-based assay for the identification of KCC2-positive modulators. | 2010-02 |
|
| A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel. | 2009-11-01 |
|
| Thallium ions can replace both sodium and potassium ions in the glutamate transporter excitatory amino acid carrier 1. | 2008-12-02 |
|
| Preliminary SAR studies on non-apamin-displacing 4-(aminomethylaryl)pyrrazolopyrimidine K(Ca) channel blockers. | 2008-10-15 |
|
| Initial SAR studies on apamin-displacing 2-aminothiazole blockers of calcium-activated small conductance potassium channels. | 2008-10-01 |
|
| A novel assay of Gi/o-linked G protein-coupled receptor coupling to potassium channels provides new insights into the pharmacology of the group III metabotropic glutamate receptors. | 2008-04 |
|
| Selective positive modulation of the SK3 and SK2 subtypes of small conductance Ca2+-activated K+ channels. | 2007-07 |
|
| Relationship between pore occupancy and gating in BK potassium channels. | 2006-05 |
|
| A thallium-sensitive, fluorescence-based assay for detecting and characterizing potassium channel modulators in mammalian cells. | 2004-12 |
|
| In vitro interactions of thallium with components of the glutathione-dependent antioxidant defence system. | 2004-09 |
|
| Interaction of Tl+ with product complexes of fructose-1,6-bisphosphatase. | 2003-05-02 |
|
| Altered expression pattern of polycystin-2 in acute and chronic renal tubular diseases. | 2002-07 |
|
| Kcnkø: single, cloned potassium leak channels are multi-ion pores. | 2001-01 |
|
| Studies on thallium toxicity, its tissue distribution and histopathological effects in rats. | 2000-07 |
|
| Safety and diagnostic accuracy of dipyridamole-thallium imaging in the elderly. | 1988-03 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:35:29 GMT 2025
by
admin
on
Mon Mar 31 18:35:29 GMT 2025
|
| Record UNII |
AD84R52XLF
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C637
Created by
admin on Mon Mar 31 18:35:29 GMT 2025 , Edited by admin on Mon Mar 31 18:35:29 GMT 2025
|
||
|
DSLD |
2064 (Number of products:18)
Created by
admin on Mon Mar 31 18:35:29 GMT 2025 , Edited by admin on Mon Mar 31 18:35:29 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000127664
Created by
admin on Mon Mar 31 18:35:29 GMT 2025 , Edited by admin on Mon Mar 31 18:35:29 GMT 2025
|
PRIMARY | |||
|
231-138-1
Created by
admin on Mon Mar 31 18:35:29 GMT 2025 , Edited by admin on Mon Mar 31 18:35:29 GMT 2025
|
PRIMARY | |||
|
4496
Created by
admin on Mon Mar 31 18:35:29 GMT 2025 , Edited by admin on Mon Mar 31 18:35:29 GMT 2025
|
PRIMARY | |||
|
AD84R52XLF
Created by
admin on Mon Mar 31 18:35:29 GMT 2025 , Edited by admin on Mon Mar 31 18:35:29 GMT 2025
|
PRIMARY | |||
|
Thallium
Created by
admin on Mon Mar 31 18:35:29 GMT 2025 , Edited by admin on Mon Mar 31 18:35:29 GMT 2025
|
PRIMARY | |||
|
m10674
Created by
admin on Mon Mar 31 18:35:29 GMT 2025 , Edited by admin on Mon Mar 31 18:35:29 GMT 2025
|
PRIMARY | Merck Index | ||
|
AD84R52XLF
Created by
admin on Mon Mar 31 18:35:29 GMT 2025 , Edited by admin on Mon Mar 31 18:35:29 GMT 2025
|
PRIMARY | |||
|
C95188
Created by
admin on Mon Mar 31 18:35:29 GMT 2025 , Edited by admin on Mon Mar 31 18:35:29 GMT 2025
|
PRIMARY | |||
|
DTXSID2036035
Created by
admin on Mon Mar 31 18:35:29 GMT 2025 , Edited by admin on Mon Mar 31 18:35:29 GMT 2025
|
PRIMARY | |||
|
1311633
Created by
admin on Mon Mar 31 18:35:29 GMT 2025 , Edited by admin on Mon Mar 31 18:35:29 GMT 2025
|
PRIMARY | RxNorm | ||
|
30440
Created by
admin on Mon Mar 31 18:35:29 GMT 2025 , Edited by admin on Mon Mar 31 18:35:29 GMT 2025
|
PRIMARY | |||
|
7440-28-0
Created by
admin on Mon Mar 31 18:35:29 GMT 2025 , Edited by admin on Mon Mar 31 18:35:29 GMT 2025
|
PRIMARY | |||
|
SUB33791
Created by
admin on Mon Mar 31 18:35:29 GMT 2025 , Edited by admin on Mon Mar 31 18:35:29 GMT 2025
|
PRIMARY | |||
|
D013793
Created by
admin on Mon Mar 31 18:35:29 GMT 2025 , Edited by admin on Mon Mar 31 18:35:29 GMT 2025
|
PRIMARY | |||
|
5359464
Created by
admin on Mon Mar 31 18:35:29 GMT 2025 , Edited by admin on Mon Mar 31 18:35:29 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |